Skip to main content
Fig. 5 | World Journal of Surgical Oncology

Fig. 5

From: Identifying subgroups deriving the most benefit from PD-1 checkpoint inhibition plus chemotherapy in advanced metastatic triple-negative breast cancer: a systematic review and meta-analysis

Fig. 5

Forest plot of meta-analysis of progression-free survival (PFS) based on based on presence of de novo metastasis between patients receiving immunotherapy plus chemotherapy (ICT) and CT alone. Immunotherapy mainly consisted of PD-1/PD-L1 inhibitors. The PFS data for recurrent mTNBC patients in KEYNOTE-355 study was reported based on recurrence within 12 months (KEYNOTE-355) and beyond 12 months (KEYNOTE-355*). KEYNOTE-355 study reported the recurrent mTNBC patients based on 12 months

Back to article page

World Journal of Surgical Oncology

ISSN: 1477-7819

Contact us